TW200602034A - Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors - Google Patents

Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors

Info

Publication number
TW200602034A
TW200602034A TW094109805A TW94109805A TW200602034A TW 200602034 A TW200602034 A TW 200602034A TW 094109805 A TW094109805 A TW 094109805A TW 94109805 A TW94109805 A TW 94109805A TW 200602034 A TW200602034 A TW 200602034A
Authority
TW
Taiwan
Prior art keywords
cyclooxygenase
intraocular pressure
monotherapy
modulation
selective inhibitors
Prior art date
Application number
TW094109805A
Other languages
Chinese (zh)
Inventor
Jaime L Masferrer
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TW200602034A publication Critical patent/TW200602034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions and methods for modulating intraocular pressure in a subject. More particularly, the invention provides a therapy for the treatment of hypotony comprising administering to a subject a cyclooxygenase-2 selective inhibitor.
TW094109805A 2004-03-31 2005-03-29 Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors TW200602034A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55808104P 2004-03-31 2004-03-31

Publications (1)

Publication Number Publication Date
TW200602034A true TW200602034A (en) 2006-01-16

Family

ID=35124824

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094109805A TW200602034A (en) 2004-03-31 2005-03-29 Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors

Country Status (2)

Country Link
TW (1) TW200602034A (en)
WO (1) WO2005097110A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation

Also Published As

Publication number Publication date
WO2005097110A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
MY151032A (en) Treatment of tnf? related disorders
TW200738263A (en) ANG2 and VEGF inhibitor combinations
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
DK1809280T3 (en) Mitotic kinesin inhibitors and methods for their use
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
UA88655C2 (en) S-mirtazapine for the treatment of hot flush
WO2007130501A3 (en) Combination therapy for treatment of cancer
TW200508233A (en) Chk-1 inhibitors
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
WO2004093816A3 (en) Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
WO2007132269A8 (en) Dub3 as a cancer therapy target
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
TW200633720A (en) Medicinal composition for diabetic
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
TW200732317A (en) Benzochromene derivatives
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors